Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 7
2012 29
2013 51
2014 65
2015 77
2016 88
2017 106
2018 102
2019 107
2020 89
2021 84
2022 66
2023 82
2024 38

Text availability

Article attribute

Article type

Publication date

Search Results

842 results

Results by year

Filters applied: . Clear all
Page 1
Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial.
Lingvay I, Asong M, Desouza C, Gourdy P, Kar S, Vianna A, Vilsbøll T, Vinther S, Mu Y. Lingvay I, et al. JAMA. 2023 Jul 18;330(3):228-237. doi: 10.1001/jama.2023.11313. JAMA. 2023. PMID: 37354562 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the efficacy and safety of once-weekly icodec vs once-daily insulin degludec in people with insulin-naive type 2 diabetes. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-masked, noninferiority, treat-to-target, phase 3a trial conducted …
OBJECTIVE: To evaluate the efficacy and safety of once-weekly icodec vs once-daily insulin degludec in people with insulin-nai …
Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial.
Philis-Tsimikas A, Asong M, Franek E, Jia T, Rosenstock J, Stachlewska K, Watada H, Kellerer M. Philis-Tsimikas A, et al. Lancet Diabetes Endocrinol. 2023 Jun;11(6):414-425. doi: 10.1016/S2213-8587(23)00093-1. Epub 2023 May 3. Lancet Diabetes Endocrinol. 2023. PMID: 37148899 Clinical Trial.
ONWARDS 2 aimed to assess the efficacy and safety of once-weekly icodec versus once-daily insulin degludec (degludec) in basal insulin-treated type 2 diabetes. ...
ONWARDS 2 aimed to assess the efficacy and safety of once-weekly icodec versus once-daily insulin degludec (degludec) in basal …
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á. Gastaldelli A, et al. Lancet Diabetes Endocrinol. 2022 Jun;10(6):393-406. doi: 10.1016/S2213-8587(22)00070-5. Epub 2022 Apr 22. Lancet Diabetes Endocrinol. 2022. PMID: 35468325 Clinical Trial.
From an overall mean baseline LFC of 15.71% (SD 8.93), the absolute reduction in LFC at week 52 was significantly greater for the pooled tirzepatide 10 mg and 15 mg groups (-8.09%, SE 0.57) versus the insulin degludec group (-3.38%, 0.83). The estimated treatment di …
From an overall mean baseline LFC of 15.71% (SD 8.93), the absolute reduction in LFC at week 52 was significantly greater for the pooled tir …
Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open-label, multinational, randomised, controlled, non-inferiority trial.
Mathiesen ER, Alibegovic AC, Corcoy R, Dunne F, Feig DS, Hod M, Jia T, Kalyanam B, Kar S, Kautzky-Willer A, Marchesini C, Rea RD, Damm P; EXPECT study group. Mathiesen ER, et al. Lancet Diabetes Endocrinol. 2023 Feb;11(2):86-95. doi: 10.1016/S2213-8587(22)00307-2. Epub 2023 Jan 6. Lancet Diabetes Endocrinol. 2023. PMID: 36623517 Clinical Trial.
BACKGROUND: Insulin degludec (degludec) is a second-generation basal insulin with an improved pharmacokinetic-pharmacodynamic profile compared with first-generation basal insulins, but there are few data regarding its use during pregnancy. ...
BACKGROUND: Insulin degludec (degludec) is a second-generation basal insulin with an improved pharmacokinetic-pharmacodynamic …
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, Bray R, Rodríguez Á. Ludvik B, et al. Lancet. 2021 Aug 14;398(10300):583-598. doi: 10.1016/S0140-6736(21)01443-4. Epub 2021 Aug 6. Lancet. 2021. PMID: 34370970 Clinical Trial.
The primary efficacy endpoint was non-inferiority of tirzepatide 10 mg or 15 mg, or both, versus insulin degludec in mean change from baseline in HbA(1c) at week 52. ...The ETD versus insulin degludec ranged from -9.8 kg to -15.2 kg for tirzepatide (p& …
The primary efficacy endpoint was non-inferiority of tirzepatide 10 mg or 15 mg, or both, versus insulin degludec in mean chan …
Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.
Russell-Jones D, Babazono T, Cailleteau R, Engberg S, Irace C, Kjaersgaard MIS, Mathieu C, Rosenstock J, Woo V, Klonoff DC. Russell-Jones D, et al. Lancet. 2023 Nov 4;402(10413):1636-1647. doi: 10.1016/S0140-6736(23)02179-7. Epub 2023 Oct 17. Lancet. 2023. PMID: 37863084 Free article. Clinical Trial.
BACKGROUND: ONWARDS 6 compared the efficacy and safety of once-weekly subcutaneous insulin icodec (icodec) and once-daily insulin degludec (degludec) in adults with type 1 diabetes. METHODS: This 52-week (26-week main phase plus a 26-week safety extension), randomis …
BACKGROUND: ONWARDS 6 compared the efficacy and safety of once-weekly subcutaneous insulin icodec (icodec) and once-daily insulin …
Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL Around Spontaneous Exercise Sessions in Adults with Type 1 Diabetes: A Randomized Cross-Over Trial (ULTRAFLEXI-1 Study).
Moser O, Müller A, Aberer F, Aziz F, Kojzar H, Sourij C, Obermayer A, Abbas F, Birnbaumer P, Lenz J, Mursic I, Sternad C, Hönger L, Ziko H, Pferschy PN, Tripolt N, Sourij H. Moser O, et al. Diabetes Technol Ther. 2023 Mar;25(3):161-168. doi: 10.1089/dia.2022.0422. Epub 2023 Jan 2. Diabetes Technol Ther. 2023. PMID: 36516429 Clinical Trial.
Aims: In the ULTRAFLEXI-1 study, we compared basal insulin Glargine 300 U/mL (IGlar U300) and insulin Degludec 100 U/mL (IDeg U100) for time below range <70 mg/dL (TBR(<70); 3.9 mmol/L) in two different doses (100% and 75% of the regular dose) when used around …
Aims: In the ULTRAFLEXI-1 study, we compared basal insulin Glargine 300 U/mL (IGlar U300) and insulin Degludec 100 U/mL (IDeg …
Insulin Degludec/Liraglutide: A Review in Type 2 Diabetes.
Greig SL, Scott LJ. Greig SL, et al. Drugs. 2015 Sep;75(13):1523-34. doi: 10.1007/s40265-015-0448-0. Drugs. 2015. PMID: 26242767 Review.
In insulin-naive patients, add-on insulin degludec/liraglutide provided significantly greater improvements in glycated haemoglobin (HbA1c) levels than add-on insulin degludec, liraglutide or placebo, or unchanged GLP-1 receptor agonists (i.e. liragluti …
In insulin-naive patients, add-on insulin degludec/liraglutide provided significantly greater improvements in glycated haemogl …
Insulin degludec + liraglutide: a complementary combination.
Stinkens K, Peene B, Mathieu C. Stinkens K, et al. Expert Opin Biol Ther. 2016 Sep;16(9):1171-7. doi: 10.1080/14712598.2016.1217328. Epub 2016 Aug 5. Expert Opin Biol Ther. 2016. PMID: 27484310 Review.
AREAS COVERED: Recently a fixed-ratio combination therapy of the basal insulin degludec and the glucagon-like peptide-1 analogue liraglutide has been developed and approved by the EMA. ...The fixed-ratio combination of insulin degludec and liraglutide …
AREAS COVERED: Recently a fixed-ratio combination therapy of the basal insulin degludec and the glucagon-like peptide-1 analog …
842 results

Searches related to "insulin degludec"